Timing of kidney replacement therapy in tumor lysis syndrome
Timing of Renal Replacement Therapy Initiation in Tumor Lysis Syndrome
This study tests whether starting kidney replacement therapy early versus waiting changes 30-day kidney recovery in adults with tumor lysis syndrome–related acute kidney injury.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 10 sites (Angers and 9 other locations) |
| Trial ID | NCT06889974 on ClinicalTrials.gov |
What this trial studies
This is a retrospective, multicenter ICU study using data from French hospitals collected between 2013 and 2023 to compare early versus delayed initiation of renal replacement therapy (RRT) in patients with tumor lysis syndrome (TLS) and acute kidney injury (AKI). Investigators will extract clinical and laboratory data to classify timing of RRT and track renal function, RRT use, and mortality. The primary outcome is renal function at 30 days after ICU admission, with additional outcomes including 30-day and one-year mortality and ongoing dialysis dependence. The analysis aims to determine whether timing of RRT initiation is associated with better short- and longer-term renal outcomes in this specific population.
Who should consider this trial
Good fit: Ideal candidates are adults treated in participating ICUs with tumor lysis syndrome after chemotherapy who developed AKI and have complete medical records available for 2013–2023.
Not a fit: Patients without TLS, those under 18, or those with incomplete records or who opposed data use would not be included and are unlikely to benefit from this analysis.
Why it matters
Potential benefit: If successful, the results could clarify when to start RRT in TLS patients and help improve kidney recovery and possibly reduce mortality.
How similar studies have performed: Randomized trials in broader AKI populations have found little difference between early and delayed RRT, but TLS-specific data are limited and this question remains largely untested in TLS patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged ≥18 years. * Hospitalized in the ICU between January 1, 2013, and December 31, 2023. * Diagnosed with a hematologic malignancy or solid tumor requiring chemotherapy. * Diagnosed with TLS based on the presence of two or more biochemical criteria (e.g., hyperkalemia, hyperphosphatemia, hyperuricemia, hypocalcemia) within 3 days before or 7 days after chemotherapy initiation. Exclusion Criteria: * Patient or family opposition to data collection for research purposes. * Incomplete medical records that preclude data extraction.
Where this trial is running
Angers and 9 other locations
- CHU d'Angers — Angers, France (Withdrawn)
- Hôpital Pellegrin — Bordeaux, France (Recruiting)
- Hôpital la cavale blanche — Brest, France (Recruiting)
- CHU Dupuytren 1 — Limoges, France (Withdrawn)
- Hôtel-Dieu — Nantes, France (Recruiting)
- CHR d'Orléans — Orléans, France (Recruiting)
- CH de Pau — Pau, France (Recruiting)
- Centre Urgences-Réanimations — Rennes, France (Recruiting)
- IUCT-O Hopital Purpan — Toulouse, France (Recruiting)
- Hôpital Bretonneau — Tours, France (Recruiting)
Study contacts
- Study coordinator: Arthur ORIEUX
- Email: arthur.orieux@chu-bordeaux.fr
- Phone: 05 56 70 56 79
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.